(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 November 2006 (23.11.2006)

PCT

(10) International Publication Number
WO 2006/123257 A3

(51) International Patent Classification:
C07D 413/14 (2006.01) *A61P 25/18* (2006.01)
C07D 401/14 (2006.01) *A61P 25/32* (2006.01)
A61K 31/4245 (2006.01) *A61P 25/34* (2006.01)
A61K 31/415 (2006.01) *A61P 25/36* (2006.01)
A61P 25/22 (2006.01)

(21) International Application Number:
PCT/IB2006/002047

(22) International Filing Date: 17 May 2006 (17.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0510141.5 18 May 2005 (18.05.2005) GB

(71) Applicant *(for all designated States except US)*: **ADDEX PHARMACEUTICALS SA** [CH/CH]; 12 Chemin des Aulx, CH-1228 Plan-les-Ouates (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GAGLIARDI, Stefania** [IT/IT]; NiKem Research Srl, Via Zambeletti, 25, I-20021 Baranzante (Milan) (IT). **LE POUL, Emmanuel** [FR/CH]; Addex Pharmaceutical SA, 12, chemin des Aulx, CH-1228 Plan les Ouates (FR). **LINGARD, Iain** [GB/IT]; NiKem Research Srl, Via Zambeletti 25, I-20021 Baranzate (GB). **PALOMBI, Giovanni** [IT/IT]; NiKem Research Srl, Via Zambeletti 25, I-20021 Baranzate (IT). **POLI, Sonia, Maria** [IT/CH]; Addex Pharmaceuticals SA, 12, Chemin Des Aulx, CH-1228 Plan-les-Ouates (CH). **ROCHER, Jean-Philippe** [FR/CH]; Addex Pharmaceuticals SA, 12, chemin des Aulx, CH-1228 Plan les Ouates (CH).

(74) Agent: **DAVIES, Johnathan, Mark**; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*


(88) Date of publication of the international search report:
3 May 2007

(48) Date of publication of this corrected version:
21 June 2007

(15) Information about Corrections:
see PCT Gazette No. 25/2007 of 21 June 2007
Previous Correction:
see PCT Gazette No. 11/2007 of 15 March 2007

[Continued on next page]

(54) Title: PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS



I

(I)

(57) Abstract: The present invention provides new compounds of formula (I) as positive allosteric modulators of metabotropic receptors - subtype 5 ("mGluR5") which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluR5 is involved. W represents (C_4-C_7)cycloalkyl, (C_3-C_7)heterocycloalkyl , (C_3-C_7)heterocycloalkyl-(C_1-C_3)alkyl or (C_3-C_7)heterocycloalkenyl ring; P represents a (C_5-C_7)heteroeycloalkyl, (C_5-C_7)heterocycloalkenyl ring or a heteroaryl group of formula (a), (b), (c), (d), (e), (f), (g), (h), (i). Q denotes a cycloalkyl, an aryl or heteroaryl group of formula (j), (k), (l), (m), (n). A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR_8C(=O)-, -NR_8C(=O)-O-, -NR_8C(=O)-NR_9, NR_8S(=O)$_2$-, -C(=O)NR_8-, -O-C(=O)NR_8-, -S-, -S(=O)-, -S(=O)$_2$-, -S(C=O)$_2NR_8$-, -C(=O)-O-, -O-C(=O)-, -C(=NR_8)NR_9-, C(C=NOR_8)NR_9- , -NR_8C(=NOR_9)-, =N-O-, -O-N=CH- or a group aryl or heteroaryl of formula, (o), (p), (q), (r), (s), (t), (u), (v), (w), (x). The other substituents are defined in the claims.

WO 2006/123257 A3

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.